ADMS - Adamas Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Adamas Pharmaceuticals, Inc.

1900 Powell Street
Suite 750
Emeryville, CA 94608
United States
510-450-3500
http://www.adamaspharma.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees154

Key Executives

NameTitlePayExercisedYear Born
Dr. Gregory T. WentCo-Founder, Chairman & CEO816.52kN/A1964
Mr. Alfred G. MerriweatherChief Financial Officer604.6kN/A1954
Dr. Rajiv PatniChief Medical Officer627.17kN/A1969
Mr. Christopher B. PrentissChief Accounting OfficerN/AN/A1975
Ms. Jennifer J. RhodesChief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec.N/AN/A1970
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Corporate Governance

Adamas Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 7. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.